Benchmark cuts Criteo stock price target on weaker outlook By Investing.com

Benchmark cut its price target on Criteo to $25 from $30 while keeping a Buy rating, citing a larger-than-expected outlook reduction. Second-quarter contribution ex-TAC and adjusted EBITDA were guided 9% and 13% below Street estimates, and full-year 2026 guidance now implies a low-single-digit constant-currency decline with recovery delayed to Q4. Management blamed macro pressure, weak fashion/travel demand, and slower product adoption, even as first-quarter EPS of $0.73 beat consensus and revenue came in above expectations.

Analysis

The market is still treating this as a clean-demand story, but the more important issue is margin durability: when a platform cuts guide this sharply, the next leg is usually not just weaker spend but weaker pricing leverage on renewal cohorts. That creates a second-order drag on mix, because the highest-quality budgets tend to be the first to get re-optimized, leaving a more promotional, lower-ROI customer base that compresses contribution ex-TAC even if gross spend stabilizes.

The selloff also looks like it is discounting optionality asymmetrically. If the redomiciling catalyst is real, the equity may be a two-part setup: near-term fundamental disappointment, followed by a 12-24 month rerating if corporate structure changes unlock index inclusion, tax efficiency, or capital return capacity. That said, the path dependency is ugly — any further deterioration in large-client retention or slower new-product adoption would push the recovery story out beyond 2026, making the multiple support less relevant in the interim.

Consensus may be underestimating how much of the weakness is self-inflicted versus cyclical. If management can isolate client-specific execution issues, the stock can rebound faster than the guide cut implies; if not, this becomes a credibility problem that lowers estimate revisions across the Street for several quarters. The key tell is whether the U.S. performance-media cohort and fashion exposure stabilize into Q3, because that would argue the base business is intact and the current valuation is pricing in a worse-than-reality drawdown.

Key Decisions for Investors

• Avoid chasing the bounce in CRTO for the next 2-4 weeks; wait for either a post-earnings stabilization or a reset in estimate revisions before buying the dip.
• For long-only portfolios, consider a starter long in CRTO only on weakness near 1.0x-1.2x forward sales with a 6-12 month horizon; upside is rerating on 2027 redomiciling optionality, downside is another guide cut if client losses persist.
• Pair trade: long CRTO vs short a higher-multiple adtech peer with more retail-media exposure over the next 3-6 months; CRTO has deeper valuation support if the issue stays company-specific rather than sector-wide.
• Use CRTO January 2027 call spreads to express the redomiciling thesis with defined risk; this captures the corporate-action optionality while limiting exposure to another two quarters of execution noise.
• If large-client metrics remain weak into the next update, take profits or cut long exposure quickly — the stock can stay value-trapped for 2-3 quarters if investor confidence in guidance credibility erodes further.